1. Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation, text, pictures, graphics and other files and the selection and arrangement thereof are copyrighted materials of Ovid or its licensors, all rights reserved. Except for the Authorized Use specified above, you may not copy, modify or distribute any of the Online Service materials. You may not "mirror" any material contained on this Online Service on any other server. Any unauthorized use of any material contained on this Online Service may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.

2. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 2 Table 1 Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. Schulman, Sam; Kearon, Clive; Kakkar, Ajay; Mismetti, Patrick; Schellong, Sebastian; Eriksson, Henry; Baanstra, David; Schnee, Janet; Goldhaber, Samuel New England Journal of Medicine. 361(24):2342-2352, December 10, 2009. Table 1. Characteristics of the Patients and Treatments.

3. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 3 Figure 1 Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. Schulman, Sam; Kearon, Clive; Kakkar, Ajay; Mismetti, Patrick; Schellong, Sebastian; Eriksson, Henry; Baanstra, David; Schnee, Janet; Goldhaber, Samuel New England Journal of Medicine. 361(24):2342-2352, December 10, 2009. Figure 1. Cumulative Risk of Recurrent Venous Thromboembolism or Related Death during 6 Months of Treatment among Patients Randomly Assigned to Dabigatran or Warfarin.

4. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 4 Table 2 Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. Schulman, Sam; Kearon, Clive; Kakkar, Ajay; Mismetti, Patrick; Schellong, Sebastian; Eriksson, Henry; Baanstra, David; Schnee, Janet; Goldhaber, Samuel New England Journal of Medicine. 361(24):2342-2352, December 10, 2009. Table 2. Efficacy and Bleeding Outcomes.

5. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 5 Figure 2 Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. Schulman, Sam; Kearon, Clive; Kakkar, Ajay; Mismetti, Patrick; Schellong, Sebastian; Eriksson, Henry; Baanstra, David; Schnee, Janet; Goldhaber, Samuel New England Journal of Medicine. 361(24):2342-2352, December 10, 2009. Figure 2. Cumulative Risks of a First Event of Major Bleeding and of Any Bleeding among Patients Randomly Assigned to Dabigatran or Warfarin.The hazard ratio with dabigatran for major bleeding at 6 months was 0.82 (95% CI, 0.45 to 1.48; P=0.38), and the hazard ratio with dabigatran for any bleeding at 6 months was 0.71 (95% CI, 0.59 to 0.85; P<0.001).

6. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 6 Table 3 Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. Schulman, Sam; Kearon, Clive; Kakkar, Ajay; Mismetti, Patrick; Schellong, Sebastian; Eriksson, Henry; Baanstra, David; Schnee, Janet; Goldhaber, Samuel New England Journal of Medicine. 361(24):2342-2352, December 10, 2009. Table 3. Adverse Events during the Double-Dummy Phase and during the Total Period of Treatment.